news releases

23 November 2020

Merck to Acquire OncoImmune

Acquisition adds to Merck’s suite of clinical programs in response to SARS-CoV-2/COVID-19 Merck will accelerate development of CD24Fc, a candidate for the treatment of patients with severe and critical COVID-19 CDKENILWORTH, N.J., & ROCKVILLE, Md.--Merck (NYSE: MRK),…
Read more...
24 September 2020

OncoImmune’s SACCOVID™ (CD24Fc) Exhibits Superb Therapeutic Efficacy—A Potential Breakthrough in Treating Severe and Critical COVID-19

OncoImmune, Inc. today announced that it has closed enrollment of the Phase III SAC-COVID clinical trial (NCT04317040) and releases topline results from the pre-planned interim efficacy analysis. Data from 203 participants (75% of the planned…
Read more...
23 September 2020

OncoImmune Launches First-in-human Clinical Trial for ONC-392 – The anti-CTLA-4 Antibody that Preserves CTLA4 Recycling for Safer and More Effective Immunotherapy

OncoImmune, Inc. announced today that it has dosed the first patient in the first-in-human clinical trial of ONC-392, its novel, next generation anti-CTLA-4 antibody, at the University of California (UC) Davis Comprehensive Cancer Center on…
Read more...
09 September 2020

OncoImmune, Inc. Raises $56 Million Series B Financing for Novel Cancer and COVID-19 Therapeutics

OncoImmune, Inc. announced the completion of a $56 million financing in Series B equity co-led by HM Capital and a blue-chip investor. Existing investors, 3E Bioventures Capital and Kaitai Capital, as well as additional new…
Read more...
14 June 2020

OncoImmune, Inc. Reports Progress on its Phase III Clinical Trial testing CD24Fc for Severe and Critical COVID-19

OncoImmune, Inc. reached an important milestone in its Phase III clinical trial testing the safety and clinical efficacy of CD24Fc for severe and critical COVID-19 patients (SAC-COVID) on June 9, 2020. The first 70 patients…
Read more...
21 April 2020

OncoImmune Starts Phase III Clinical Trial Testing the Power of Dampening Inflammation to Virus-induced Cellular Injury in Severe COVID-19 Patients

OncoImmune, Inc. initiated its Phase III clinical trial testing the safety and efficacy of CD24Fc in hospitalized COVID-19 patients (SAC-COVID) at the University of Maryland Baltimore Medical Center on April 20, 2020. The national trial…
Read more...

About Us

Based in Rockville, Maryland, OncoImmune is a
privately-held, clinical-stage biopharmaceutical
company that is actively engaged in the discovery
and development of biopharmaceuticals for the
treatment of cancer and autoimmune disease.

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.